iShares Healthcare Innovation UCITS ETF

TELO

ARKG

Telomir reported peer-reviewed preclinical data indicating that Telomir-Zn improves survival and reduces hepatic copper in a Wilson’s disease model. Key findings include reduced copper-driven ROS amplification, lower liver injury biomarkers, and improved locomotor performance in zebrafish. The company plans to continue its Wilson’s disease program and advance its Telomir-1 TNBC program toward Phase 1/2 clinical initiation.

TradingView

Telomir Pharmaceuticals

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

iShares US Pharma

VG Health

Health Care Select Sector SPDR

iShares Biotechnology ETF

VanEck Biotech ETF

Telomir Reports Peer-Reviewed Preclinical Telomir-Zn Data Showing Dose-Dependent Survival & Reduced Hepatic Copper

The global stigmasterol-rich plant sterols market is projected to reach USD 1,281.42 million by 2036, driven by rising cardiovascular health awareness and demand for functional foods. The market is transitioning towards standardized formulations and regulatory support, with significant growth in applications across food, nutraceuticals, and pharmaceuticals. Key growth regions include India, Germany, and China, with a forecast CAGR of 3.8% from 2026 to 2036. The market is bolstered by increasing consumer preference for plant-based wellness solutions and regulatory approvals for health claims.

MorningStar

Stigmasterol-Rich Plant Sterols Market to Reach USD 1,281.42 Million by 2036 as Cardiovascular Health Awareness and Functional Food Demand Expand Globally

The Global Luminex Multiplex Assays Market is projected to grow from USD 1.82 billion in 2025 to USD 3.89 billion by 2033, at a CAGR of 10.0%. This growth is driven by the rising demand for high-throughput biomarker profiling and standardized testing workflows. Key factors include the efficiency of multiplex systems, regulatory support for standardized panels, and the expansion of outsourced research models. However, challenges such as validation complexity and elevated costs may impact adoption rates.

fidelity

Luminex Multiplex Assays Market Projected to Reach USD 3.89 Billion by 2033, Driven by Rising Demand for High-Throughput Biomarker Profiling and Standardized Multiplex Testing Workflows: Verified Market Research

Chinese rehabilitation robot manufacturers are expanding into international markets, leveraging technological advancements despite facing regulatory challenges. Experts highlight the rapid development of robot technology and the importance of partnerships for market entry. The global rehabilitation equipment market is projected to grow significantly, driven by an aging population and increasing health issues. Companies are adapting their strategies to meet varying market receptiveness, particularly in Europe and the U.S.

Yicai

Chinese Rehab Robot Makers Leverage Tech Advantages to Expand Overseas, Experts Say

AI is transforming the pharmaceutical industry, particularly in clinical trial design. Trialynx, an AI-powered platform, helps optimize trials by predicting failure points and improving protocols. CEO Angela Schwab emphasizes the need for lean trial designs to reduce patient burden and enhance data collection efficiency. She highlights the importance of considering patient experiences and site capabilities in trial planning to minimize operational challenges and improve success rates. The conversation underscores the potential of AI to address high failure rates in clinical trials by leveraging data and innovative approaches.

Pharmexec

<![CDATA[Transforming Clinical Trial Design and Avoiding AI Wrappers: Q&A with Angela Schwab]]>

HEAL

DOCT

The rise in life expectancy is outpacing the increase in healthy life years, creating a significant gap that presents investment opportunities in healthcare. Bellevue Asset Management emphasizes longevity in its strategies, focusing on healthspan as a key economic variable. Key investment drivers include prevention through digital health monitoring, minimally invasive interventions, and targeted treatments for age-related diseases. The Bellevue Healthcare ETF targets companies that improve clinical outcomes and reduce healthcare costs, aiming to capitalize on the longevity trend in the healthcare market.

FiNews

Legal & General UCITS ETF PLC - L&G Healthcare Breakthrough UCITS ETF AccumUSD

Abbott Laboratories

DexCom

IRhythm

Stryker

Intuitive Surgical

Novo Nordisk AS

Eli Lilly

Amgen

Biogen

Eisai Co., Ltd.

Merck

AstraZeneca

AstraZeneca PLC

Longevity: Where Medical Progress Creates Economic Value

THRL

SCHE

Inspiration Healthcare Group PLC has reported a significant change in major holdings. Redworth Portfolio Ltd has crossed the voting rights threshold, now holding 16.577% of the company's voting rights as of January 23, 2026. This is an increase from the previous holding of 15.016%. The notification was made on January 25, 2026, and the company is based in the UK, while Redworth Portfolio Ltd is registered in Israel.

London Stock Exchange

Target Healthcare REIT PLC

Southern Cross Healthcare Group PLC

REG - Inspiration Health - Holding(s) in Company

iShares Healthcare Innovation UCITS ETF(HEAL.UK)

Telomir Reports Peer-Reviewed Preclinical Telomir-Zn Data Showing Dose-Dependent Survival & Reduced Hepatic Copper

Stigmasterol-Rich Plant Sterols Market to Reach USD 1,281.42 Million by 2036 as Cardiovascular Health Awareness and Functional Food Demand Expand Globally

Luminex Multiplex Assays Market Projected to Reach USD 3.89 Billion by 2033, Driven by Rising Demand for High-Throughput Biomarker Profiling and Standardized Multiplex Testing Workflows: Verified Market Research

Chinese Rehab Robot Makers Leverage Tech Advantages to Expand Overseas, Experts Say

<![CDATA[Transforming Clinical Trial Design and Avoiding AI Wrappers: Q&A with Angela Schwab]]>